The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease

被引:33
作者
Heikkinen, H
Nutt, JG
LeWitt, PA
Koller, WC
Gordin, A
机构
[1] Orion Corp, Orion Pharma, Res Ctr, FIN-02101 Espoo, Finland
[2] Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA
[3] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI USA
[4] Wayne State Univ, Sch Med, Dept Psychiat, Detroit, MI USA
[5] Wayne State Univ, Sch Med, Dept Behav Neurosci, Detroit, MI USA
[6] Clin Neurosci Ctr, Southfield, MI USA
[7] Univ Miami, Dept Neurol, Miami, FL 33152 USA
关键词
entacapone; dose response; L-Dopa; Parkinson's disease;
D O I
10.1097/00002826-200105000-00006
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We performed a double-blind, placebo-controlled, randomized, crossover, multiple-dose study on entacapone in 25 patients with Parkinson's disease with levodopa (L-Dopa) treatment-related fluctuations. A run-in period was followed by four 2-week treatment periods during which the patients took 4 to 6 daily doses of L-Dopa concomitantly with 100, 200, or 400 mg of entacapone or with placebo. The effects were assessed at the end of each period: the inhibition of soluble catechol-O-methyltransferase (S-COMT) activity in red blood cells and the plasma concentrations of entacapone, L-Dopa, and 3-O-methyldopa (3-OMD) were measured and clinical effects assessed on an 18-hour home diary. Twenty-one patients completed the study. Entacapone decreased the COMT activity from predose level: 100 mg by 25%, 200 mg by 33%, and 400 mg by 32% (p < 0.001 vs. placebo for each dose). Correspondingly, the 3-OMD concentrations decreased by 39%, 54%, and 66% with 100-, 200-, and 400-mg doses, respectively. The elimination half-life of L-Dopa was prolonged by 23% (p < 0.05), 26% (p < 0.001), and 48% (p < 0.001), and the area under the curve of L-Dopa increased by 17% (p < 0.05), 27% (p < 0.001), and 37% (p < 0.001) with the increasing doses. Despite a significant decrease in the daily dose of L-Dopa, entacapone decreased the proportion of daily "off" time: 100 mg by 11%, 200 mg by 18%, and 400 mg by 20% compared with placebo. However, this decrease was not statistically significant for any of the doses in this small patient population. The dyskinetic "on" time did not increase with different doses of entacapone. All doses were well tolerated, and no severe adverse events were reported. The study showed that repeated dosing of entacapone inhibits the COMT activity in a dose-dependent manner and thereby reduces the loss of L-Dopa to 3-OMD. Therefore, the area under the curve of L-Dopa is increased and the patient's clinical condition improved.
引用
收藏
页码:150 / 157
页数:8
相关论文
共 21 条
[1]   EFFECT OF ENTACAPONE, A COMT INHIBITOR, ON THE PHARMACOKINETICS AND METABOLISM OF LEVODOPA AFTER ADMINISTRATION OF CONTROLLED-RELEASE LEVODOPA-CARBIDOPA IN VOLUNTEERS [J].
AHTILA, S ;
KAAKKOLA, S ;
GORDIN, A ;
KORPELA, K ;
HEINAVAARA, S ;
KARLSSON, M ;
WIKBERG, T ;
TUOMAINEN, P ;
MANNISTO, PT .
CLINICAL NEUROPHARMACOLOGY, 1995, 18 (01) :46-57
[2]   METABOLISM OF ORALLY ADMINISTERED L-DOPA IN PARKINSONISM [J].
CALNE, DB ;
KAROUM, F ;
RUTHVEN, CRJ ;
SANDLER, M .
BRITISH JOURNAL OF PHARMACOLOGY, 1969, 37 (01) :57-+
[3]   CLINICAL PHARMACOKINETICS OF ANTI-PARKINSONIAN DRUGS [J].
CEDARBAUM, JM .
CLINICAL PHARMACOKINETICS, 1987, 13 (03) :141-178
[4]  
Fahn S., RECENT DEV PARKINSON, V2, P153, DOI DOI 10.1002/ANA.410220556
[5]  
Gibaldi M. P., 1982, PHARMACOKINETICS
[6]  
ILLI A, 1994, INT J CLIN PHARM TH, V32, P582
[7]  
Jones B., 1989, DESIGN ANAL CROSS OV
[8]  
KARLSSON M, 1992, PHARM BIOMED ANAL, V8, P593
[9]   THE EFFECT OF CATECHOL-O-METHYL TRANSFERASE INHIBITION BY ENTACAPONE ON THE PHARMACOKINETICS AND METABOLISM OF LEVODOPA IN HEALTHY-VOLUNTEERS [J].
KERANEN, T ;
GORDIN, A ;
HARJOLA, VP ;
KARLSSON, M ;
KORPELA, K ;
PENTIKAINEN, PJ ;
RITA, H ;
SEPPALA, L ;
WIKBERG, T .
CLINICAL NEUROPHARMACOLOGY, 1993, 16 (02) :145-156
[10]  
KERANEN T, 1994, EUR J CLIN PHARMACOL, V46, P151